Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 6, 2004, Pages 679-687

  Emanueli, C ^a,b   Madeddu, Paolo ^a,c  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b Molecular and Cellular Medicine   (Croatia)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Angiogenesis; Diabetes; Endothelium; Gene therapy; Kallikrein; Kinins; VEGF

Indexed keywords

ANGIOGENIC FACTOR; CYCLOOXYGENASE 2; CYTOKINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR B1; G PROTEIN COUPLED RECEPTOR B2; HYPOXIA INDUCIBLE FACTOR; KALLIKREIN; KININ; KININOGEN; NITRIC OXIDE; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN; PROSTANOID; PROTEIN KINASE B; PROTEIN SUBUNIT; SERINE PROTEINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTERY OCCLUSION; CELL PROLIFERATION; COLLATERAL CIRCULATION; DIABETES MELLITUS; DISEASE MODEL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; GENE TRANSFER; HUMAN; HYPERTENSION; ISCHEMIA; MICROANGIOPATHY; NONHUMAN; PROPHYLAXIS; PROTECTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SKELETAL MUSCLE; TISSUE REGENERATION; WOUND HEALING;

ANIMALS; CEREBROVASCULAR ACCIDENT; COAGULANTS; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HUMANS; HYPERTENSION; KALLIKREINS; MICE; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042667898     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Emanueli C, Salis MB, Pinna A et al. Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002; 106: 993-9.
2. Frisbee JC. Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol 2003; 285: H104-H111.
3. Frustaci A, Kajstura J, Chimenti C et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-32.
4. Abaci A, Oguzhan A, Kahraman S et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239-42.
5. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342: 1040-2.
6. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-63.
7. Taniyama Y, Morishita R, Hiraoka K et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-50.
8. Tea BS, Dam TV, Moreau P, Hamet P, de Blois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats: temporal regulation and spatial heterogeneity. Hypertension 1999; 34: 229-35.
9. Antonios TFT, Singer DRJ, Markandu ND, Mortimer PS, Mac-Gregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension 1999; 33: 998-1001.
10. Hernandez N, Tarres SH, Finol HJ, Vera O. Capillary changes in skeletal muscle of patients with essential hypertension. Anat Rec 1999; 256: 425-32.
11. Chen IH, Prewitt RL, Dawell RF. Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle. Am J Physiol 1981; 241: H306-H310.
12. Emanueli C, Salis MB, Stacca T et al. Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 2001; 38: 136-41.
13. Emanueli C, Minasi A, Zacheo A et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in a mouse model of hindlimb ischemia. Circulation 2001; 103: 125-32.
14. Isner JM. Myocardial gene therapy. Nature 2002; 415: 234-9. Review.
15. Couffinhal T, Silver M, Kearney M et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE -/-mice. Circulation 1999; 99: 3188-98.
16. Gennaro G, Menard C, Michaud SE, Rivard A. Age-dependent impairment of reendothelialization after arterial injury: role of vascular endothelial growth factor. Circulation 2003; 107: 230-3.
17. Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin 1998; 38: 89-102. Review.
18. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor 165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001; 37: 2126-30.
19. Henry TD, Abraham JA. Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. Curr Interv Cardiol Rep 2000; 2: 228-41.
20. Rajagopalan S, Mahler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-8.
21. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
22. Mayfield RK, Shimojo N, Jaffa AA. Skeletal muscle kallikrein: potential role in metabolic regulation. Diabetes 1996; 45: S20-S30.
23. Duka I, Shenauda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001; 38: 1355-60.
24. Emanueli C, Bonaria Salis M, Stacca T et al. Targeting kinin B1 receptor for therapeutic neovascularization. Circulation 2002; 105: 360-6.
25. Emanueli C, Maestri R, Corradi D et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999; 100: 2359-65.
26. Brull D, Dhamaralt S, Myerson J et al. Bradykinin B2BKR receptor polymorphism and left-ventricular response. Lancet 2001; 358: 1155-56.
27. Maestri R, Milia AF, Salis MB et al. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003; 41: 1151-5.
28. Emanueli C, Zacheo A, Minasi A et al. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 2000; 20: 2379-85.
29. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
30. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
31. Emanueli C, Salis B, Stacca T et al. Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol 2002; 135: 87-92.
32. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8-13.
33. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P. Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 2004; 53: 1096-103.
34. Xia CF, Yin H, Borlongan CV, Chao L, Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452-9.
35. Emanueli C, Schratzberger P, Kirchmair R, Madeddu P. Paracrine control of vascularization and neurogenesis by neurotrophins. Br J Pharmacol 2003; 140: 614-9.
36. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003; 285: H1479-H1488.
37. Tonduangu D, Hittinger L, Ghaleh B et al. Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs. Circulation 2004; 109: 114-9.
38. Porcu P, Emanueli C, Kapatsaris M, Chao J, Chao L, Madeddu P. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation 2002; 105: 67-72.
39. Porcu P, Emanueli C, Desortes E et al. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arteriascl Thromb Vasc Biol (in press).